Study on the antitumor activity of CAR-NK-92 cells targeting MSLN in gastric cancer
ZHANG Jun1 DONG Yalu2
1.Department of General Surgery, General Hospital of Xinjiang Military Region, Xinjiang Uygur Autonomous Region, Urumqi 830000, China;
2.Department of Oncology, General Hospital of Xinjiang Military Region, Xinjiang Uygur Autonomous Region, Urumqi 830000, China
Abstract：Objective To explore the antitumor activity of NK-92 cells modified with chimeric antigen receptor targeting mesothelin (MSLN) in gastric cancer. Methods The second generation chimeric antigen receptor targeting MSLN was constructed and transfected into NK-92 cells by lentivirus transfection to obtain MSLN CAR-NK-92 cells. The expression of MSLN in human gastric cancer tissues and human gastric cancer cells was detected by immunohistochemistry, flow cytometry and Western blot. The specific recognition ability and the anti-tumor activity of CAR-NK-92 cells were studied through in vitro activation and in vivo tumor inhibition experiments. Results MSLN was highly expressed in human gastric cancer tissue and tumor cells. CAR-NK-92 cells could specifically activate and lyse tumor cells. Compared with NK-92 cells transfected with an empty vector, CAR-NK-92 cells can significantly inhibited the growth of gastric cancer (P < 0.01). Conclusion CAR-NK-92 targeting MSLN has shown significant activity in vivo and in vitro to kill gastric cancer cells specific to MSLN+, which may provide a new idea in the treatment of gastric cancer.
[1] Slagter AE，Tudela B，van Amelsfoort RM，et al. Older versus younger adults with gastric cancer receiving perioperative treatment：Results from the CRITICS trial [J]. Eur J Cancer，2020，130：146-154.
[2] Ferlay J，Soerjomataram I，Dikshit R，et al. Cancer incidence and mortality worldwide：sources，methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer，2018，136（5）：E359-E386.
[3] Miliotou AN，Papadopoulou LC. CAR T-cell Therapy：A New Era in Cancer Immunotherapy [J]. Curr Pharm Biotechnol，2018，19（1）：5-18.
[4] Veluchamy JP，Kok N，van der Vliet HJ，et al. The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy：Recent Innovations and Future Developments [J]. Front Immunol，2017，8：631.
[5] Swift BE，Williams BA，Kosaka Y，et al. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model [J]. Haematologica，2012，97（7）：1020-1028.
[6] Angelo LS，Banerjee PP，Monaco-Shawver L，et al. Practical NK cell phenotyping and variability in healthy adults [J]. Immunol Res，2015，62（3）：341-356.
[7] Klingemann H，Boissel L，Toneguzzo F. Natural Killer Cells for Immunotherapy-Advantages of the NK-92 Cell Line over Blood NK Cells [J]. Front Immunol，2016，7：91.
[8] Yan Y，Steinherz P，Klingemann HG，et al. Antileukemia activity of a natural killer cell line against human leukemias [J]. Clin Cancer Res，1998，4（11）：2859-2868.
[9] Nowakowska P，Romanski A，Miller N，et al. Clinical grade manufacturing of genetically modified，CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies [J]. Cancer Immunol Immunother，2018，67（1）：25-38.
[10] Lv J，Zhao R，Wu D，et al. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer [J]. J Hematol Oncol，2019，12（1）：18.
[11] Sotoudeh M，Shirvani SI，Merat S，et al. MSLN（Mesothelin），ANTXR1（TEM8），and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma [J]. J Cell Biochem，2019，120（4）：5010-5017.
[12] Yu S，Li A，Liu Q，et al. Chimeric antigen receptor T cells：a novel therapy for solid tumors [J]. J Hematol Oncol，2017，10（1）：78.
[13] Srivastava S，Riddell SR. Chimeric Antigen Receptor T Cell Therapy：Challenges to Bench-to-Bedside Efficacy [J]. J Immunol，2018，200（2）：459-468.
[14] Pascal V，Schleinitz N，Brunet C，et al. Comparative analysis of NK cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions [J]. Eur J Immunol，2004，34（10）：2930-2940.
[15] Suck G，Odendahl M，Nowakowska P，et al. NK-92：an ′off-the-shelf therapeutic′ for adoptive natural killer cell-based cancer immunotherapy [J]. Cancer Immunol Immunother，2016，65（4）：485-492.
[16] Arai S，Meagher R，Swearingen M，et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma：a phase Ⅰ trial [J]. Cytotherapy，2008，10（6）：625-632.
[17] Zhang C，Oberoi P，Oelsner S，et al. Chimeric Antigen Receptor-Engineered NK-92 Cells：An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity [J]. Front Immunol，2017，8：533.
[18] Adusumilli PS，Cherkassky L，Villena-Vargas J，et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity [J]. Sci Transl Med，2014，6（261）：261ra151.
[19] Gong JH，Maki G，Klingemann HG. Characterization of a human cell line（NK-92）with phenotypical and functional characteristics of activated natural killer cells [J]. Leukemia，1994，8（4）：652-658.
[20] 王志华.NK细胞抗肿瘤临床转化研究进展[J].中国肿瘤生物治疗杂志，2016，23（3）：419-426.
2020, Vol. 17 
京公网安备 11010502046598号